An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients
Phase of Trial: Phase II/III
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Nalbuphine (Primary)
- Indications Prurigo nodularis
- Focus Adverse reactions
- Sponsors Trevi Therapeutics
- 20 Jul 2017 Status changed from active, no longer recruiting to completed, according to Trevi Therapeutics media release.
- 13 Oct 2016 According to Trevi Therapeutics media release, company expects to complete this study in the third quarter of 2017.
- 26 Sep 2016 Last checked against ClinicalTrials.gov record.